Literature DB >> 8421079

Clinical review 41: Current therapy for osteoporosis.

R R Recker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8421079     DOI： 10.1210/jcem.76.1.8421079

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  8 in total

1.  Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.

Authors:  D Agnusdei; C Gennari; L Bufalino
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

2.  Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin.

Authors:  G Pan; S M Vickers; A Pickens; J O Phillips; W Ying; J A Thompson; G P Siegal; J M McDonald
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

3.  Fas expression prevents cholangiocarcinoma tumor growth.

Authors:  A Pickens; G Pan; J M McDonald; S M Vickers
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

4.  Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect.

Authors:  Kyeong-Ok Choi; Inae Lee; Sae-Yeol-Rim Paik; Dong Eun Kim; Jung Dae Lim; Wie-Soo Kang; Sanghoon Ko
Journal:  J Med Food       Date:  2012-10       Impact factor: 2.786

5.  Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women.

Authors:  M Atteritano; S Mazzaferro; A Frisina; M L Cannata; A Bitto; R D'Anna; F Squadrito; I Macrì; N Frisina; M Buemi
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

Review 6.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

7.  Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling.

Authors:  Jin Dai; Yalin Li; Honghao Zhou; Jie Chen; Minhu Chen; Zhousheng Xiao
Journal:  Int J Biol Sci       Date:  2013-11-21       Impact factor: 6.580

8.  Effect of whole soy and isoflavones daidzein on bone turnover and inflammatory markers: a 6-month double-blind, randomized controlled trial in Chinese postmenopausal women who are equol producers.

Authors:  Zhao-Min Liu; Bailing Chen; Shuyi Li; Guoyi Li; Di Zhang; Suzanne C Ho; Yu-Ming Chen; Jing Ma; Huang Qi; Wen-Hua Ling
Journal:  Ther Adv Endocrinol Metab       Date:  2020-06-18       Impact factor: 3.565
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.